Tempus AI, Inc. · NASDAQ:TEM
Tempus AI — Q3 2026 Earnings Presentation
24 slides from Tempus AI's earnings presentation, Nov 2, 2026
Slide 1: Q3’26 Financial Results
Q3’26 Financial Results November 2, 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements that reflect Tempus AI, Inc.’s (the “Company” or “Tempus”) current expectations and projections with respect to, among other things, its financial condition, results of operations, plans, objectives, future performance and business. For
Slide 3: Tempus has built the operating system for precision medicine
Tempus has built the operating system for precision medicine Tempus’ moat is built on embedded integrations, proprietary multi-modal data, and continuously expanding outcome-linked datasets enhanced Insights delivered to point of care through the connection between its Actionable intelligence AI pla
Slide 4: Precision medicine powered by diagnostic intelligence
Precision medicine powered by diagnostic intelligence Clinical Testing EHR Integrations Research AI & Technology Leveraging our broad portfolio Embedding diagnostic Converting multimodal patient Deploying advanced technologies of assays to ensure the right intelligence directly into health data into
Slide 5: Our Diagnostics business is comprehensive and spans hereditary risk, therapy selection, and MRD & monitoring
Our Diagnostics business is comprehensive and spans hereditary risk, therapy selection, and MRD & monitoring, fueling our models with longitudinal data Therapy selection Tailored testing* Hereditary risk xT, xF Tissue + Liquid Biopsy HRD UGT1A1 DPYD MRD & disease assessment IPS TO PurIST™ MMR xR DNA
Slide 6: Data generated through Diagnostics creates a virtuous cycle of AI-enabled intelligence
Data generated through Diagnostics creates a virtuous cycle of AI-enabled intelligence As more clinicians use our AI Applications they contribute more data to our platform, creating a self-reinforcing cycle of intelligence. Data Foundation Applications Model This network effect has led to compoundin
Slide 7: Q3’26 Financial Results
‘TEMPUS Q3’26 Financial Results
Slide 8: Q3’26 Financial Highlights
Q3’26 Financial Highlights $411.5M $25.6M 32% 33% Total revenue Adj. EBITDA Oncology Volume Data & Applications Growth Revenue Growth 23% Growth YoY 1,633% Improvement YoY Gross profit increased 27% to $266.7 million led by growth in Data & Applications Net loss of $(14.9) million compared to $(80.0)
Slide 9: Q3 Revenue delivers 23% growth YoY
Q3 Revenue delivers 23% growth YoY 23% $411.5M Data and Applications $334.2M Oncology Hereditary Life Sciences/ Research Q3 2025 Q3 2026 9
Slide 10: Diagnostics drives growth with revenue and Oncology volume expansion
Diagnostics drives growth with revenue and Oncology volume expansion Oncology Volume Oncology and Hereditary achievements fueling Diagnostics growth ~101,500 Q3 Diagnostics Highlights ~77,000 ● 32% YoY Oncology volume growth ● 28% YoY Oncology revenue growth ● 20% YoY Diagnostics revenue growth Q3 2
Slide 11: MRD volumes accelerate and provide long-term growth opportunity
MRD volumes accelerate and provide long-term growth opportunity MRD Volume 12,000 MRD Highlights ● 300% YoY growth with only ~15% of 9,000 salesforce selling today ● xM tumor naive represents ~5% of total MRD volume today, providing massive opportunity for upside 6,500 ● Cleared regulatory review fo
Slide 12: Therapy Selection ASP expected to rise significantly over the next several years
Therapy Selection ASP expected to rise significantly over the next several years Tailwinds from reimbursement expected to drive ASP growth of >$750* over next several years Reimbursement Milestones Illustrative path to >$2600 ASP* ASP with broader FDA approval of tumor only xT CDx enables entire DNA
Slide 13: Data & Applications growth accelerates on strong partnership expansion
Data & Applications growth accelerates on strong partnership expansion Data & Applications Revenue Q3 Data & Apps Highlights ● 33% growth YoY, with Insights growing 29% ● Licensing bookings reach ~$500M YTD $108.1M ● Announced collaboration with Bristol Myers Squibb (NYSE: BMY) to license oncology $
Slide 14: Performance summary
Performance summary Q3 2026 Scaling Diagnostics and Data & Applications fueling operating leverage and Adjusted EBITDA expansion Q3 2026 Q3 2025 Change Revenue $411.5M $334.2M 23% Gross profit $266.7M $209.9M 27% Loss from operations $(56.9)M $(61.0)M 7% Non-GAAP income (loss) from operations $14.4M
Slide 15: 2026 Guidance
2026 Guidance Q4 FULL YEAR $1.60 - $1.605B REVENUE $457- $463 million of revenue ● Continued strong oncology growth ● Hereditary growth rate improving in Q4 ~25% growth year-over-year ● Data & Applications growth of >30% vs Q4 2025 ~$65M ADJUSTED EBITDA ~$34 million ● Continued quarter over quarter
Slide 16: Balancing near-term reinvestment with long-term Adjusted EBITDA expansion
Balancing near-term reinvestment with long-term Adjusted EBITDA expansion We expect ~25% top-line growth over the next 3 years supported by continued strength in Diagnostics and expanding scale in our Data and Applications business. Over the next several years, we plan to reinvest the majority of in
Slide 17: Appendix
‘TEMPUS Appendix
Slide 18: Non-GAAP Total Gross Profit & Gross Margin
Three months Ended September 30, Non-GAAP Total Gross 2026 2025 Profit & Gross Margin Net Revenue $ 411,537 $ 334,206 Gross profit and gross profit margin reconciliation Cost of revenues 144,836 124,264 Gross profit $ 266,701 $ 209,942 Unaudited In thousands, except percentages Stock-based compensation
Slide 19: Non-GAAP Diagnostics
Three months Ended September 30, Non-GAAP 2026 2025 Diagnostics Diagnostics revenue $303,470 $252,878 Gross profit and gross profit Cost of revenues, diagnostics 114,042 98,643 margin reconciliation Gross profit, diagnostics $ 189,428 $ 154,235 Unaudited In thousands, except percentages Stock-based com
Slide 20: Non-GAAP Data and Applications
Three months Ended September 30, Non-GAAP 2026 2025 Data and Applications Data and applications revenue $ 108,067 $ 81,328 Gross profit and gross profit Cost of revenues, data and applications 30,794 25,621 margin reconciliation Gross profit, data and applications $ 77,273 $ 55,707 Unaudited In thousan
Slide 21: Non-GAAP Operating expenses reconciliation
Three months Ended September 30, 2026 2025 Non-GAAP Technology R&D Stock-based compensation expense $ 45,708 7,954 $38,087 5,463 Employer payroll tax related to stock-based Operating expenses compensation 615 278 reconciliation Non-GAAP technology R&D $ 37,139 $ 32,346 Research & development $46,000
Slide 22: Non-GAAP Income (Loss) from Operations
Three months Ended September 30, Non-GAAP 2026 2025 Income (Loss) from Loss from operations $ (56,864) $(60,996) Operations Stock-based compensation expense 48,074 33,979 Employer payroll tax related to stock-based 2,749 1,039 compensation Acquisition related expenses 1 3,728 552 Unaudited In thousa
Slide 23: Non-GAAP EPS reconciliation
Three months Ended September 30, 2026 2025 Non-GAAP Net loss $ (14,851) $(79,982) EPS reconciliation Fair value changes 1 (41,490) 1,255 Stock-based compensation expense 48,074 33,979 Employer payroll tax related to stock-based 2,749 1,039 compensation Unaudited Acquisition related expenses 2 3,728
Slide 24: Adjusted EBITDA reconciliation
Three months Ended September 30, 2026 2025 Adjusted EBITDA Net loss $(14,851) $ (79,982) reconciliation Interest income (3,985) (4,600) Interest expense 6,701 15,399 Depreciation 7,338 8,120 Amortization 18,894 18,911 Unaudited Provision for income taxes 35 276 In thousands EBITDA $ 14,132 $ (41,876